Shire targets Allergan's dry-eye market share by pricing Xiidra at $5K per year--right on par with Restasis

Shire logo

What’s a quick way to nab market share from a competitor? Roll out a superior product at the same price--and that’s what Shire believes it’s doing with newly approved dry eye med Xiidra.

The Dublin-based drugmaker has decided to roll out its new product--green-lighted by the FDA earlier this month--at about $5,000 per year, according to Evercore ISI analyst Umer Raffat. A 30-day supply will cost $426.73--which just so happens to be the exact same price of a 30-day supply of rival Allergan product Restasis.

With the move, Shire forgoes an opportunity to slap a premium price on its med. Some industry watchers had expected as much; after all, Xiidra is the first med indicated specifically for dry eye, with blockbuster Restasis technically meant for “tear production.”

Free Daily Newsletter

Like this story? Subscribe to FiercePharma!

Biopharma is a fast-growing world where big ideas come along daily. Our subscribers rely on FiercePharma as their must-read source for the latest news, analysis and data on drugs and the companies that make them. Sign up today to get pharma news and updates delivered to your inbox and read on the go.

But doing so could have had consequences. Though the label is “clearly better” for Xiidra, a “meaningful premium” may have spurred some maneuvering from payers to make Restasis the go-to med, Raffat wrote to clients shortly after Shire’s regulatory win.

Now, it’ll be up to Shire’s sales and marketing teams to talk up Xiidra’s advantages and lure patients away from Restasis. But as Allergan commercial chief Bill Meury has said, Shire might not have an easy time doing so.

For one, Restasis boasts a payer coverage rate of about 85%, he pointed out on February’s Q4 conference call. And for two, some 70% of Restasis patients are repeat users, suggesting their loyalties lie with Allergan.

Even with the introduction of Xiidra, “I just don't see any major disruption,” he told investors.

Analysts don’t necessarily disagree. As Raffat figures, even if Xiidra does grab some Restasis volume--say, 30% over time, he estimates--Allergan may be able to offset about 10% to 15% of that through a series of price increases. And Bernstein’s Ronny Gal wrote to clients earlier this month that Allergan’s “power of incumbency” will make for what will likely be a “stable oligopoly” between the two meds.

Related Articles:
Shire's new dry-eye approval means it's time for an Allergan showdown
Allergan's Restasis defense stumbles at FDA as Shire loads up lifitegrast assault 
Allergan pooh-poohs threat from Shire's prospective dry-eye drug 
Shire's back on track with its dry-eye threat to Allergan's Restasis 
Shire's eye drug setback gives Allergan's Restasis a temporary reprieve

Suggested Articles

An injection that's under FDA priority review as a monthly HIV therapy can suppress the virus even if given every two months, a phase 3 has shown.

Pfizer and Astellas are chasing a new nod for prostate cancer drug Xtandi, and thanks to the FDA, they might not have to wait that long.

Sanofi lost an appeal challenging the ban on its dengue vaccine Dengvaxia in the Philippines, despite an ongoing outbreak there.